Hans Jeppsson
Finanzdirektor/CFO bei VICORE PHARMA HOLDING AB
Vermögen: 8 227 $ am 30.04.2024
Aktive Positionen von Hans Jeppsson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VICORE PHARMA HOLDING AB | Finanzdirektor/CFO | 01.01.2017 | - |
Public Communications Contact | 01.01.2017 | - | |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | - | - |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Hans Jeppsson
Ehemalige bekannte Positionen von Hans Jeppsson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Danske Bank A/S (Sweden) | Analyst-Equity | - | - |
Ausbildung von Hans Jeppsson
University of Gothenburg | Doctorate Degree |
Handelshögskolan i Göteborg | Doctorate Degree |
Statistik
International
Schweden | 7 |
Operativ
Doctorate Degree | 2 |
Graduate Degree | 2 |
Analyst-Equity | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VICORE PHARMA HOLDING AB | Health Technology |
Private Unternehmen | 3 |
---|---|
Danske Bank A/S (Sweden) | Finance |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Health Technology |
- Börse
- Insiders
- Hans Jeppsson
- Erfahrung